MannKind (MNKD) Misses Q1 EPS by 2c
Get Alerts MNKD Hot Sheet
Revenue Growth %: +48.9%
Financial Fact:
Interest income: 28K
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
MannKind (NASDAQ: MNKD) reported Q1 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04).
The Company’s portion of the loss sharing under the Sanofi License Agreement was $5.5 million for the first quarter of 2016. The total amount owed to Sanofi is currently $68.8 million, including accrued interest of $2.8 million.
Cash and cash equivalents at March 31, 2016 were $27.7 million, compared to $59.1 million at December 31, 2015. In February 2016, an upfront fee of $250,000 was received pursuant to the previously announced collaboration and license agreement with Receptor Life Sciences. In addition, $467,000 was received from exercises of stock options by employees. Currently, $30.1 million remains available for borrowing under the amended loan arrangement with The Mann Group. A recently filed universal shelf registration statement became effective along with a prospectus supplement for a $50.0 million ATM facility.
For earnings history and earnings-related data on MannKind (MNKD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
- Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!